Lorus Therapeutics Inc. (LOR.TO) said Wednesday it has got the approval of the U.S. Patent and Trademark Office for its patent regarding the lead small molecule anticancer drug LOR-253.
The patent, which was originally set to expire in May 2026, was granted a patent adjustment that extends its expiry date to February 2028.
The US patent covers LOR-253 composition of matter and methods of treating cancer. Patents with similar protection for LOR-253 have been issued in Canada and Australia, and are pending in Europe, Japan, and China.
LOR-253 is in a Phase I clinical trial that assesses the safety profile and antitumor activity of LOR-253. Patients with advanced or metastatic solid tumors who are unresponsive to conventional therapy, or for which no effective therapy is available, are currently being recruited for this clinical study.
For comments and feedback: editorial@rttnews.com